MCID: LKC003
MIFTS: 52

Leukocyte Disease

Categories: Blood diseases, Immune diseases

Aliases & Classifications for Leukocyte Disease

MalaCards integrated aliases for Leukocyte Disease:

Name: Leukocyte Disease 12 15
Leukocyte Disorders 45 74
Abnormality of Leukocytes 30

Classifications:



External Ids:

Disease Ontology 12 DOID:9500
ICD9CM 36 288 288.9
MeSH 45 D007960
SNOMED-CT 69 54097007
ICD10 34 D72.9
UMLS 74 C0023510

Summaries for Leukocyte Disease

Disease Ontology : 12 A hematopoietic system disease that is located in white blood cells.

MalaCards based summary : Leukocyte Disease, also known as leukocyte disorders, is related to leukocyte adhesion deficiency, type i and neutrophilia, hereditary. An important gene associated with Leukocyte Disease is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Ciprofloxacin and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include breast, myeloid and bone, and related phenotypes are Reduced mammosphere formation and hematopoietic system

Wikipedia : 77 White blood cells (also called leukocytes or leucocytes and abbreviated as WBCs) are the cells of the... more...

Related Diseases for Leukocyte Disease

Diseases related to Leukocyte Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Related Disease Score Top Affiliating Genes
1 leukocyte adhesion deficiency, type i 10.9
2 neutrophilia, hereditary 10.9
3 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.6 BCL6 MYC
4 tracheal lymphoma 10.6 CD5 MME
5 heart lymphoma 10.6 BCL6 MME
6 ovary sarcoma 10.6 CD34 MYC
7 ovarian angiosarcoma 10.6 CD34 MYC
8 colon lymphoma 10.6 BCL6 CD19 CD5
9 seborrheic infantile dermatitis 10.6 CSF2 IL5
10 indolent myeloma 10.5 B2M MYOM2
11 plasmablastic lymphoma 10.5 BCL6 CD38 MYC
12 bladder lymphoma 10.5 CD19 CD5 MME
13 breast myofibroblastoma 10.5 CD34 MME
14 encapsulated thymoma 10.5 CD38 MME
15 lung lymphoma 10.5 BCL6 CD19 CD5
16 multicentric castleman disease 10.5 BCL6 IL5 IL6
17 richter's syndrome 10.5 CD38 CD5 MYC
18 lymphoblastic lymphoma 10.5 BCL6 CD5 MME
19 lymphoma 10.5 BAX BCL6 CCND1 MYC
20 adult lymphoma 10.5 CD5 CSF3 MYC
21 breast lymphoma 10.5 BCL6 CD5
22 orbital granuloma 10.5 CD34 CSF3
23 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 IL5 IL6
24 nasopharyngeal disease 10.5 CASP3 CCND1 MYC
25 bagassosis 10.5 IL5 IL6
26 pharynx cancer 10.5 CASP3 CCND1 MYC
27 reticulosarcoma 10.5 B2M BCL6 CASP3
28 cervix disease 10.5 CASP3 CCND1 MYC
29 central nervous system leukemia 10.5 CD19 MME
30 trigonitis 10.5 CD34 CSF3
31 ecthyma 10.5 CSF2 CSF3 MYOM2
32 lymphoma, hodgkin, classic 10.5 BCL6 CD19 CD5 MME
33 follicular lymphoma 10.5 BCL6 CCND1 MME MYC
34 diffuse infiltrative lymphocytosis syndrome 10.5 CD19 CD38 SDC1
35 b-cell expansion with nfkb and t-cell anergy 10.5 B2M CD38 CD5
36 marginal zone b-cell lymphoma 10.5 BCL6 CCND1 CD5 MME
37 peripheral t-cell lymphoma 10.5 BCL6 CD5 MME
38 diffuse large b-cell lymphoma 10.5 BCL6 CD5 MME MYC
39 lymphocytic leukemia 10.5 CD38 CD5 MME MYC
40 intravascular large b-cell lymphoma 10.5 B2M BCL6 CD5 MME
41 upper respiratory tract disease 10.5 IL5 IL6 MYOM2
42 b cell prolymphocytic leukemia 10.5 CD19 CD38 CD5 MYC
43 male reproductive organ cancer 10.5 CASP3 CCND1 MYC
44 colonic disease 10.5 CASP3 CCND1 MYC
45 bronchial disease 10.5 CSF2 IL5 IL6
46 anterior scleritis 10.5 B2M CD19 CD5 IL5
47 primary effusion lymphoma 10.5 BCL6 CASP3 IL6 MYC
48 cll/sll 10.5 CCND1 CD38 CD5 MME
49 peripheral nervous system neoplasm 10.5 CASP3 CD34 MYC
50 human immunodeficiency virus infectious disease 10.5 B2M CD38 IL6

Comorbidity relations with Leukocyte Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Leukocyte Disease:



Diseases related to Leukocyte Disease

Symptoms & Phenotypes for Leukocyte Disease

GenomeRNAi Phenotypes related to Leukocyte Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 BCL6 CCND1 CCR6 CD34 CD5 CSF3

MGI Mouse Phenotypes related to Leukocyte Disease:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.34 B2M BAX BCL6 CASP3 CCND1 CCR6
2 immune system MP:0005387 10.3 B2M BAX BCL6 CASP3 CCND1 CCR6
3 homeostasis/metabolism MP:0005376 10.28 B2M BAX BCL6 CASP3 CCND1 CCR6
4 cellular MP:0005384 10.27 B2M BAX BCL6 CASP3 CCND1 CD19
5 endocrine/exocrine gland MP:0005379 10.16 B2M BAX BCL6 CASP3 CCND1 CD38
6 integument MP:0010771 10.1 B2M CASP3 CCND1 CD19 CD34 CD5
7 digestive/alimentary MP:0005381 10.02 B2M CASP3 CCND1 CD19 IL5 IL6
8 neoplasm MP:0002006 9.85 B2M BAX CCND1 CD19 CD34 CSF2
9 liver/biliary system MP:0005370 9.8 B2M BCL6 CD19 IL5 IL6 MME
10 reproductive system MP:0005389 9.65 B2M BAX BCL6 CASP3 CCND1 CSF2
11 respiratory system MP:0005388 9.17 BAX BCL6 CASP3 CCND1 CSF2 IL5

Drugs & Therapeutics for Leukocyte Disease

Drugs for Leukocyte Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 518)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 85721-33-1 2764
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 124-94-7 31307
3
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
4
Micafungin Approved, Investigational Phase 4,Phase 2,Phase 1 235114-32-6 477468 3081921
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
6
Piperacillin Approved Phase 4,Phase 2,Not Applicable 66258-76-2 43672
7
Tazobactam Approved Phase 4,Phase 2,Not Applicable 89786-04-9 123630
8
Meropenem Approved, Investigational Phase 4,Phase 2 119478-56-7, 96036-03-2 441130 64778
9
Vancomycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 1404-90-6 14969 441141
10
Ceftazidime Approved Phase 4,Phase 3,Phase 2 72558-82-8, 78439-06-2 5481173
11
Gemcitabine Approved Phase 4,Phase 2 95058-81-4 60750
12
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 53-03-2 5865
13
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
14
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867
15
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
16
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
17
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
18
Vincristine Approved, Investigational Phase 4,Phase 2 2068-78-2, 57-22-7 5978
19
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
20
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
21
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4, 65-46-3 6253
22
Cisplatin Approved Phase 4,Phase 3,Phase 2 15663-27-1 2767 441203 84093
23
Methotrexate Approved Phase 4,Phase 3,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
24
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 114977-28-5 148124
25
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123774-72-1, 83869-56-1
26
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 90566-53-3 62924
27
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
28
Ofloxacin Approved Phase 4,Phase 3,Not Applicable 82419-36-1 4583
29
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
30
Levofloxacin Approved, Investigational Phase 4,Phase 3,Not Applicable 100986-85-4 149096
31
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 2 84625-61-6 55283
32
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
33
Tobramycin Approved, Investigational Phase 4,Phase 3 32986-56-4 36294 5496
34
Imipenem Approved Phase 4,Not Applicable 64221-86-9, 74431-23-5 104838
35
Doripenem Approved, Investigational Phase 4 148016-81-3 73303
36
Teicoplanin Approved, Investigational Phase 4 61036-62-2
37
Omalizumab Approved, Investigational Phase 4,Phase 2,Phase 1 242138-07-4
38
Budesonide Approved Phase 4,Phase 3,Phase 2,Not Applicable 51333-22-3 5281004 63006
39
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 171228-49-2 147912
40
Sulfamethoxazole Approved Phase 4,Phase 2 723-46-6 5329
41
Trimethoprim Approved, Vet_approved Phase 4,Phase 2 738-70-5 5578
42
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 83-43-2 6741
43
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 302-25-0
44
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-24-8 5755
45
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Not Applicable 2921-57-5
46
Cilastatin Approved, Investigational Phase 4,Not Applicable 82009-34-5 6435415 5280454
47
Lenalidomide Approved Phase 4,Phase 2,Phase 1 191732-72-6 216326
48
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 5280965 14956
49
Lansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 103577-45-3 3883
50
Dexlansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 138530-94-6, 103577-45-3 9578005

Interventional clinical trials:

(show top 50) (show all 699)
# Name Status NCT ID Phase Drugs
1 Blood Draw Validation for Ciprofloxacin Pharmacokinetic Research in Pediatric Cancer Patients Unknown status NCT02967341 Phase 4
2 Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy Unknown status NCT01571518 Phase 4 late leukostim;early leukostim
3 Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation Unknown status NCT01135589 Phase 4 Micafungin
4 Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia Unknown status NCT02463747 Phase 4 Piperacillin/tazobactam;Ceftazidim;Meropenem;Vancomycin
5 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
6 Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer Unknown status NCT00030758 Phase 4
7 Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg Completed NCT02621905 Phase 4 Sporanox;Lozanoc
8 A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen Completed NCT01107756 Phase 4 LENOGRASTIM (GRANOGYTE 34)
9 The Tobramycin Study Completed NCT00257790 Phase 4 Tobramycin once a day
10 FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy Completed NCT00125723 Phase 4
11 Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia Completed NCT02213783 Phase 4 Imipenem;Imipenem
12 Study to Reduce Duration of Antibiotic Therapy in Haematological Patients With Fever and Neutropenia Completed NCT01581333 Phase 4 Empirical antimicrobial treatment discontinuation;Standard empirical antimicrobial treatment discontinuation
13 Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients Completed NCT01401010 Phase 4 Doripenem;doripenem
14 Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients Completed NCT00454272 Phase 4 Teicoplanin;Vancomycin
15 PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia Completed NCT02805205 Phase 4 PEG-rhG-CSF
16 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
17 Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
18 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Completed NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
19 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
20 Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
21 A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency Completed NCT01289847 Phase 4
22 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
23 Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients Completed NCT01114165 Phase 4
24 Safety of Cotrimoxazole in HIV- and HAART-exposed Infants Completed NCT01086878 Phase 4 cotrimoxazole
25 Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) Completed NCT00686543 Phase 4 Posaconazole
26 Diagnosis of Septicaemia by Detection of Microbial DNA in Blood in Severe Infections Completed NCT00709358 Phase 4
27 The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia Completed NCT00632554 Phase 4 prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months
28 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
29 A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood Completed NCT00001317 Phase 4 interferon-gamma
30 Steroid Treatment for Hypereosinophilic Syndrome Recruiting NCT01524536 Phase 4 prednisone
31 Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients Recruiting NCT03823950 Phase 4 Granulocyte Colony-Stimulating Factor
32 Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia Recruiting NCT02816112 Phase 4 Ciprofloxacin;Neupogen
33 G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients Recruiting NCT03793205 Phase 4 Long-acting G-CSF;Short-acting G-CSF
34 Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO Recruiting NCT02149329 Phase 4 Discontinuation of imipenem-cilastatin or meropenem
35 EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone Recruiting NCT03781596 Phase 4 Fluticasone;Omeprazole;Placebo oral capsule
36 A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia Active, not recruiting NCT02816164 Phase 4 Neupogen
37 Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Enrolling by invitation NCT03619252 Phase 4 Standard Antibacterial Prophylaxis
38 Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma Not yet recruiting NCT03652376 Phase 4 Benralizumab
39 To Evaluate the Efficacy and Safety of PEG-rhG-CSF(Jinyouli®) in Reducing Neutropenia in Patients With Cervical Cancer Not yet recruiting NCT03206684 Phase 4 PEG-rhG-CSF;rhG-CSF
40 Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia Terminated NCT01859637 Phase 4
41 SubCutaneous (SC) Versus Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients Terminated NCT01222819 Phase 4 filgrastim
42 Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics Terminated NCT00421187 Phase 4 Liposomal amphotericin B (AmBisome®);Liposomal amphotericin B (AmBisome®)
43 Comparison of 2 Antifungal Treatment (Empirical Versus Pre-Empirical) Strategies in Prolonged Neutropenia Terminated NCT00190463 Phase 4 Amphotericin B
44 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
45 Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease Terminated NCT01147042 Phase 4 IFN-gamma
46 Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin Terminated NCT00194857 Phase 4 erythropoietin, GCSF
47 Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis Withdrawn NCT01717846 Phase 4 Group 1 or Orencia treated group
48 The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia Unknown status NCT02761460 Phase 3 PEG-rhG-CSF
49 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
50 Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma Unknown status NCT02238873 Phase 3 Pegfilgrastim

Search NIH Clinical Center for Leukocyte Disease

Cochrane evidence based reviews: leukocyte disorders

Genetic Tests for Leukocyte Disease

Genetic tests related to Leukocyte Disease:

# Genetic test Affiliating Genes
1 Abnormality of Leukocytes 30

Anatomical Context for Leukocyte Disease

MalaCards organs/tissues related to Leukocyte Disease:

42
Breast, Myeloid, Bone, Bone Marrow, B Cells, T Cells, Testes

The Foundational Model of Anatomy Ontology organs/tissues related to Leukocyte Disease:

20
White Blood Cells

Publications for Leukocyte Disease

Articles related to Leukocyte Disease:

# Title Authors Year
1
Leukocyte disorders: quantitative and qualitative disorders of the neutrophil, Part 1. ( 8559712 )
1996
2
Leukocyte disorders: quantitative and qualitative disorders of the neutrophil, part 2. ( 8775892 )
1996
3
Leukocyte function and nonmalignant leukocyte disorders. ( 8374630 )
1993
4
Diagnosis of leukocyte disorders with an automated haematology counter (Technicon H-1 analyser). ( 2802504 )
1989
5
Retinal blood velocity in patients with leukocyte disorders. ( 3190539 )
1988
6
The local inflammatory response in leukocyte disorders. ( 121576 )
1979
7
Functional leukocyte disorders. ( 471548 )
1979

Variations for Leukocyte Disease

Expression for Leukocyte Disease

Search GEO for disease gene expression data for Leukocyte Disease.

Pathways for Leukocyte Disease

Pathways related to Leukocyte Disease according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 B2M BCL6 CASP3 CCND1 CCR6 CD19
2
Show member pathways
13.39 BAX CASP3 CCND1 CCR6 CSF2 CSF3
3
Show member pathways
13.29 BAX CASP3 CCR6 CSF2 CSF3 IL5
4
Show member pathways
13.27 B2M BCL6 CASP3 CCND1 CSF2 CSF3
5
Show member pathways
12.95 BAX CASP3 CCND1 CD19 CSF3 IL6
6
Show member pathways
12.93 B2M BAX CASP3 CCND1 CSF2 IL6
7
Show member pathways
12.87 B2M CASP3 CCND1 ICOSLG IL5 IL6
8
Show member pathways
12.84 BAX CASP3 CCND1 CSF2 MYC
9 12.82 BAX CASP3 CCND1 IL5 IL6 MYC
10 12.55 B2M BCL6 CD19 CD34 CD38
11
Show member pathways
12.46 BAX CASP3 CCND1 MYC
12
Show member pathways
12.35 BAX CASP3 CCND1 MYC
13 12.34 BAX CCND1 CSF2 IL6 MYC
14
Show member pathways
12.3 CCND1 CSF2 CSF3 IL5 IL6 MYC
15
Show member pathways
12.29 CASP3 CSF2 CSF3 IL5 IL6
16 12.28 CASP3 CCND1 MYC SDC1
17 12.19 BAX BCL6 CSF2 IL6 MYC
18
Show member pathways
12.18 BAX CASP3 CCND1 MYC
19 12.14 BAX CASP3 CCND1 MYC
20 12.13 BAX CASP3 CCND1 MYC
21 12.09 BAX CASP3 CCND1 IL6 MYC
22 12 CASP3 CCND1 IL6 MYC
23 11.97 BAX BCL6 CCND1 MYC
24 11.96 BCL6 CCND1 IL6 MYC
25 11.88 BAX CASP3 CCND1 IL6
26 11.86 CASP3 CSF2 IL6
27 11.85 BAX CASP3 CCND1 MYC
28
Show member pathways
11.84 CSF2 CSF3 IL6
29 11.77 CCR6 CD34 IL5
30 11.76 CCND1 CD34 MYC
31 11.76 BAX CSF2 IL5 IL6
32
Show member pathways
11.74 CASP3 CSF2 IL5
33 11.72 CD19 CD34 CD38 CD5 CSF2 CSF3
34
Show member pathways
11.65 CCND1 CSF2 IL6
35 11.6 CSF2 CSF3 IL5 IL6
36 11.6 CD19 CD34 CD38 CSF2 IL6 MME
37 11.55 BAX CCND1 IL6
38 11.53 CSF2 CSF3 IL6
39 11.52 CSF3 IL6 SDC1
40 11.49 BAX CASP3 MYC
41 11.44 CASP3 CCND1 IL6 MYC
42 11.42 BCL6 CD19 CD34 CD38 CD5 MME
43 11.39 CSF2 CSF3 IL5 IL6
44 11.35 CCND1 IL6 MYC
45 11.32 BAX CASP3 CSF2
46 11.26 CD19 CD34 CD38 CD5 CSF2 CSF3
47 11.16 BAX CSF2 CSF3 IL5 IL6
48 11.09 CSF2 CSF3 IL5 IL6
49 11 BAX CSF2 CSF3 IL5 IL6

GO Terms for Leukocyte Disease

Cellular components related to Leukocyte Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.23 B2M CCR6 CD19 CD34 CD5 ICOSLG

Biological processes related to Leukocyte Disease according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.99 BCL6 CASP3 CD38 IL6 MYC
2 cellular response to DNA damage stimulus GO:0006974 9.92 BAX BCL6 CASP3 CCND1 MYC
3 immune response GO:0006955 9.88 B2M CCR6 CSF2 CSF3 IL5 IL6
4 response to drug GO:0042493 9.83 B2M CASP3 CCND1 CD38 MYC
5 response to organic substance GO:0010033 9.76 CASP3 CCND1 SDC1
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.73 CSF3 IL5 IL6
7 regulation of immune response GO:0050776 9.72 B2M BCL6 CD19 CD34 ICOSLG
8 response to wounding GO:0009611 9.69 BAX CASP3 MYC
9 response to estradiol GO:0032355 9.67 CASP3 CCND1 CD38 MYC
10 cellular response to organic substance GO:0071310 9.65 BAX CASP3 CCND1
11 positive regulation of B cell proliferation GO:0030890 9.63 BCL6 CD38 IL5
12 hypothalamus development GO:0021854 9.58 BAX MYC
13 negative regulation of bone resorption GO:0045779 9.57 CD38 IL6
14 response to glucocorticoid GO:0051384 9.56 CASP3 CCND1 IL6 SDC1
15 positive regulation of immunoglobulin secretion GO:0051024 9.55 IL5 IL6
16 positive regulation of podosome assembly GO:0071803 9.54 CSF2 IL5
17 positive regulation of cell proliferation GO:0008284 9.5 CCND1 CD38 CSF2 CSF3 IL5 IL6
18 re-entry into mitotic cell cycle GO:0000320 9.49 CCND1 MYC
19 apoptotic signaling pathway GO:0097190 9.46 BAX CASP3 CD38 CD5
20 cytokine-mediated signaling pathway GO:0019221 9.28 BCL6 CASP3 CCND1 CSF2 CSF3 IL5

Molecular functions related to Leukocyte Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 CSF2 CSF3 IL5 IL6
2 growth factor activity GO:0008083 8.92 CSF2 CSF3 IL5 IL6

Sources for Leukocyte Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....